Phase I/II study of a 3 weekly liposome-encapsulated doxorubicin/docetaxel/pegfligrastrim in combination with weekly trastuzumab as primary treatment in HER2 positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results